Vivos Therapeutics, Inc. (NASDAQ:VVOS) Stock Short Interest Climbs 76.1%

Posted by Geri Gentry on Oct 15th, 2026

Vivos Therapeutics, Inc. (NASDAQ:VVOS – Get Free Report) saw a large growth in short interest during the month of September. As of September 30th, there was short interest totaling 2,864,201 shares, a growth of 76.1% from the September 15th total of 1,626,351 shares. Based on an average daily volume of 8,031,092 shares, the days-to-cover ratio is presently 0.4 days. Currently, 21.1% of the company’s stock are sold short.

Vivos Therapeutics Trading Up 5.2%

VVOS stock traded up $0.01 during mid-day trading on Thursday, hitting $0.14. 3,352,905 shares of the company were exchanged, compared to its average volume of 4,719,366. The company has a market capitalization of $1.96 million, a PE ratio of -0.07 and a beta of 6.11. Vivos Therapeutics has a twelve month low of $0.13 and a twelve month high of $3.21. The firm has a fifty day simple moving average of $0.20 and a 200 day simple moving average of $0.52.

Vivos Therapeutics (NASDAQ:VVOS – Get Free Report) last released its earnings results on Friday, August 14th. The company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.10. The company had revenue of $5.15 million during the quarter, compared to the consensus estimate of $5.63 million. Vivos Therapeutics had a negative net margin of 122.00% and a negative return on equity of 2,325.64%. As a group, sell-side analysts anticipate that Vivos Therapeutics will post -1.24 earnings per share for the current year.

Hedge Funds Weigh In On Vivos Therapeutics

A hedge fund recently bought a new stake in Vivos Therapeutics stock. Sequoia Financial Advisors LLC purchased a new position in Vivos Therapeutics, Inc. (NASDAQ:VVOS – Free Report) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 24,000 shares of the company’s stock, valued at approximately $28,000. Sequoia Financial Advisors LLC owned approximately 0.18% of Vivos Therapeutics as of its most recent filing with the Securities & Exchange Commission. 26.35% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Vivos Therapeutics in a research report on Friday, July 17th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Vivos Therapeutics has an average rating of “Hold” and an average price target of $2.80.

Get Our Latest Stock Analysis on Vivos Therapeutics

Vivos Therapeutics Company Profile

(Get Free Report)

Vivos Therapeutics, Inc is a medical technology company focused on developing and commercializing non-surgical treatments for sleep-related breathing disorders and related craniofacial conditions. The company’s primary focus is obstructive sleep apnea, a disorder in which the upper airway repeatedly narrows or becomes blocked during sleep.

The company markets the Vivos System, a series of customized oral appliances designed to help reposition and support the upper airway. Its offerings include the Vivos Complete Airway Repositioning Appliance (CARE) and other dental devices intended to improve airway function during sleep.